FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Takara Bio Inc. Stock AnalysisComprehensive stock analysis for Takara Bio Inc. (TKBIF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTKBIF
TKBIF
Takara Bio Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TKBIF
Home🔹Stocks🔹Takara Bio Inc.

Takara Bio Inc.

TKBIF•OTC

Takara Bio Inc.

TKBIF•OTC
Market cap
$879.03M
Sentiment

Your view on TKBIF

Mkt Cap
$879.03M
Sentiment
Your view
TKBIF
Takara Bio Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TKBIF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Takara Bio Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Tsuyoshi Miyamura
Headquarters
7-4-38 Nojihigashi, Kusatsu, JP
Industry
Biotechnology
Sector
Healthcare
CEO
Tsuyoshi Miyamura
Headquarters
7-4-38 Nojihigashi, Kusatsu, JP
Description

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News